Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 1/20 | 0.47 |
| ▸ | F2R | P25116 | 2/20 | 0.46 |
| ▸ | KCNH3 | Q9ULD8 | 2/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | HTT | P42858 | 2/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | EPHX1 | P07099 | 6/20 | 0.40 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.39 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.39 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3662823 | 0.91 | ABL1 (0.54) | ABL1F2RKCNH3MAPTHTT | |
| SCHEMBL22176875 | 0.87 | ABL1 (0.53) | ABL1F2RKCNH3MAPTHTT | |
| SCHEMBL8667014 | 0.85 | F2R (0.56) | ABL1F2RKCNH3MAPTHTT | |
| SCHEMBL10439139 | 0.81 | ABL1 (0.54) | ABL1F2RKCNH3MAPTHTT | |
| SCHEMBL20197373 | 0.80 | MAPT (0.71) | ABL1F2RKCNH3MAPTHTT | |
| SCHEMBL2920696 | 0.80 | EPHX1 (0.59) | ABL1MAPTALDH1A1EPHX1 | |
| SCHEMBL6231348 | 0.80 | ABL1 (0.49) | ABL1F2RKCNH3MAPTHTT | |
| SCHEMBL5609022 | 0.79 | MAPT (0.69) | ABL1F2RKCNH3MAPTHTT | |
| SCHEMBL15230385 | 0.79 | MAPT (0.69) | ABL1F2RKCNH3MAPTHTT | |
| SCHEMBL4611763 | 0.79 | ABL1 (0.47) | ABL1F2RKCNH3MAPTHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8372840-B2 | Potassium channel blockers | XENTION LIMITED (GB) | 2013-02-12 | — | — | US | disclosed |
| US-20100087438-A1 | New Potassium Channel Blockers | XENTION LIMITED (GB) | 2010-04-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100087438-A1 | New Potassium Channel Blockers | KCNJ2, KCNB1, KCNJ11 | ABL1 2511/4885F2R 1291/4885KCNH3 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.